Reports of suicidality in clinical trials of montelukast
- 1 October 2009
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 124 (4), 691-696.e6
- https://doi.org/10.1016/j.jaci.2009.08.010
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitisJournal of Allergy and Clinical Immunology, 2009
- Safety and tolerability of montelukast in placebo‐controlled pediatric studies and their open‐label extensionsPediatric Pulmonology, 2009
- Predictors of Spontaneous and Systematically Assessed Suicidal Adverse Events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) StudyAmerican Journal of Psychiatry, 2009
- 5-Lipoxygenase in the Prefrontal Cortex of Suicide VictimsThe Open Neuropsychopharmacology Journal, 2008
- Suicide and Suicidal BehaviorEpidemiologic Reviews, 2008
- Effects of MK-886, a 5-lipoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of miceNeuroscience Letters, 2008
- Cross-national prevalence and risk factors for suicidal ideation, plans and attemptsThe British Journal of Psychiatry, 2008
- LeukotrienesNew England Journal of Medicine, 2007
- Mood-worsening with high-pollen-counts and seasonality: A preliminary reportJournal of Affective Disorders, 2007
- The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptorThe EMBO Journal, 2006